Daniel M Skovronsky

Summary

Publications

  1. ncbi request reprint Neurodegenerative diseases: new concepts of pathogenesis and their therapeutic implications
    Daniel M Skovronsky
    Avid Radiopharmaceuticals, Inc, Philadelphia, Pennsylvania 19104, USA
    Annu Rev Pathol 1:151-70. 2006
  2. doi request reprint Use of florbetapir-PET for imaging beta-amyloid pathology
    Christopher M Clark
    Avid Radiopharmaceuticals, Philadelphia, Pennsylvania, USA
    JAMA 305:275-83. 2011
  3. ncbi request reprint Iodinated tracers for imaging amyloid plaques in the brain
    Hang F Kung
    Departments of Radiology, Pathology and Laboratory Medicine, and Pharmacology, University of Pennsylvania, Philadelphia, PA 19104, USA
    Mol Imaging Biol 5:418-26. 2003
  4. pmc Correlation of amyloid PET ligand florbetapir F 18 binding with Aβ aggregation and neuritic plaque deposition in postmortem brain tissue
    Seok Rye Choi
    Avid Radiopharmaceutical Inc, 3711 Market Street, 7th Floor, Philadelphia, PA 19104, USA
    Alzheimer Dis Assoc Disord 26:8-16. 2012
  5. pmc Synthesis and evaluation of indolinyl- and indolylphenylacetylenes as PET imaging agents for beta-amyloid plaques
    Wenchao Qu
    Department of Radiology, University of Pennsylvania, 3700 Market Street, Room 305, Philadelphia, PA 19104, USA
    Bioorg Med Chem Lett 18:4823-7. 2008
  6. ncbi request reprint Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study
    Christopher M Clark
    Avid Radiopharmaceuticals, Philadelphia, PA, USA
    Lancet Neurol 11:669-78. 2012
  7. doi request reprint Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer's disease and cognitively normal subjects
    Abhinay D Joshi
    Avid Radiopharmaceuticals, Inc, Philadelphia, PA 19104, USA
    J Nucl Med 53:378-84. 2012
  8. doi request reprint Florbetapir f-18: a histopathologically validated Beta-amyloid positron emission tomography imaging agent
    John Lister-James
    Avid Radiopharmaceuticals, Philadelphia, PA
    Semin Nucl Med 41:300-4. 2011
  9. ncbi request reprint Detection of amyloid plaques by radioligands for Abeta40 and Abeta42: potential imaging agents in Alzheimer's patients
    Mei Ping Kung
    Department of Radiology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    J Mol Neurosci 20:15-24. 2003

Research Grants

Collaborators

Detail Information

Publications9

  1. ncbi request reprint Neurodegenerative diseases: new concepts of pathogenesis and their therapeutic implications
    Daniel M Skovronsky
    Avid Radiopharmaceuticals, Inc, Philadelphia, Pennsylvania 19104, USA
    Annu Rev Pathol 1:151-70. 2006
    ....
  2. doi request reprint Use of florbetapir-PET for imaging beta-amyloid pathology
    Christopher M Clark
    Avid Radiopharmaceuticals, Philadelphia, Pennsylvania, USA
    JAMA 305:275-83. 2011
    ..The ability to identify and quantify brain β-amyloid could increase the accuracy of a clinical diagnosis of Alzheimer disease...
  3. ncbi request reprint Iodinated tracers for imaging amyloid plaques in the brain
    Hang F Kung
    Departments of Radiology, Pathology and Laboratory Medicine, and Pharmacology, University of Pennsylvania, Philadelphia, PA 19104, USA
    Mol Imaging Biol 5:418-26. 2003
    ..Criteria for selection of radioiodinated tracers with suitable in vivo properties to detect amyloid plaques are discussed...
  4. pmc Correlation of amyloid PET ligand florbetapir F 18 binding with Aβ aggregation and neuritic plaque deposition in postmortem brain tissue
    Seok Rye Choi
    Avid Radiopharmaceutical Inc, 3711 Market Street, 7th Floor, Philadelphia, PA 19104, USA
    Alzheimer Dis Assoc Disord 26:8-16. 2012
    ..This study used human autopsy brain tissue to evaluate the correlation between in vitro florbetapir F 18 binding and Aβ density measured by established neuropathologic methods...
  5. pmc Synthesis and evaluation of indolinyl- and indolylphenylacetylenes as PET imaging agents for beta-amyloid plaques
    Wenchao Qu
    Department of Radiology, University of Pennsylvania, 3700 Market Street, Room 305, Philadelphia, PA 19104, USA
    Bioorg Med Chem Lett 18:4823-7. 2008
    ..These preliminary results identified that indolylphenylacetylene, 14, may be a good lead for further structural modification to develop a useful Abeta plaque imaging agent...
  6. ncbi request reprint Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study
    Christopher M Clark
    Avid Radiopharmaceuticals, Philadelphia, PA, USA
    Lancet Neurol 11:669-78. 2012
    ..We therefore prospectively compared the sensitivity and specificity of amyloid PET imaging with neuropathology at autopsy...
  7. doi request reprint Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer's disease and cognitively normal subjects
    Abhinay D Joshi
    Avid Radiopharmaceuticals, Inc, Philadelphia, PA 19104, USA
    J Nucl Med 53:378-84. 2012
    ..In a separate set of subjects (AD, n = 10; YHCs, n = 10), test-retest reliability was evaluated by comparing intrasubject visual read ratings and SUVrs for 2 PET images acquired within 4 wk of each other...
  8. doi request reprint Florbetapir f-18: a histopathologically validated Beta-amyloid positron emission tomography imaging agent
    John Lister-James
    Avid Radiopharmaceuticals, Philadelphia, PA
    Semin Nucl Med 41:300-4. 2011
    ..Clinical studies have demonstrated a clear correlation between in vivo PET imaging with florbetapir F-18 and postmortem histopathologic quantitation of β-amyloid in the brain...
  9. ncbi request reprint Detection of amyloid plaques by radioligands for Abeta40 and Abeta42: potential imaging agents in Alzheimer's patients
    Mei Ping Kung
    Department of Radiology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    J Mol Neurosci 20:15-24. 2003
    ..Further structural modifications of TZDM to lower the background labeling will be needed to optimize the plaque-labeling property...

Research Grants7

  1. Radiopharmaceuticals for Imaging Brain Synuclein
    Daniel Skovronsky; Fiscal Year: 2005
    ..Probes with appropriate properties will be selected for clinical development to yield an innovative product for the evaluation and diagnosis of DLB. ..
  2. AV1: F-18 Radiopharmaceutical for Imaging Amyloid Plaque
    Daniel Skovronsky; Fiscal Year: 2005
    ..Development of such a radiopharmaceutical will yield significant clinical, technological and scientific benefits that can be rapidly applied to improve the health and well being of the elderly population. ..
  3. Clinical Evaluation of IMPY SPECT for Diagnosis of Alzheimer's
    Daniel Skovronsky; Fiscal Year: 2007
    ..In addition, it will allow for scientific and technological benefits by improving our understanding of AD and catalyzing the development and evaluation of novel therapies for this devastating disease. ..
  4. 18F-FP-DTBZ for PET Imaging of Beta Cell Mass in Diabetes
    Daniel Skovronsky; Fiscal Year: 2007
    ....